6 In contrast, more advanced age (≥50 years), obesity and serum ALT levels >20 IU/L were independent predictors of significant hepatic fibrosis. These findings suggest that immediate anti-HCV treatment without performing a liver biopsy may be beneficial for patients above 50 years www.selleckchem.com/products/Tubacin.html (albeit not for elderly patients (>65 years), weighing the potential risks and benefits35), especially for obese genotype 2 or 3 patients with serum ALT concentrations >20 IU/L, because more than 80% of patients with HCV with genotype

2 or 3 achieve an SVR to standard-of-care treatment.12 Given the better antiviral response of Asian patients, who have the favourable IL28B genotype more frequently than Western individuals,36 it may be preferable to initiate antiviral treatment for young Asian patients infected with genotype 1 HCV without pathology results if serum ALT levels are above 20 IU/L. Moreover, our results suggest that even in patients with genotype 1 HCV infection, which is a well-known predictor of negative antiviral treatment response,6 high-risk factors for significant

hepatic fibrosis such as serum ALT levels of >20 IU/L, age ≥50 years and obesity may be deemed to justify an active antiviral approach, preferably with triple regimens, without liver biopsy findings. We observed severe hepatic fibrosis in about 40% of the patients with normal ALT levels (ie, less than 40 IU/L). This rate was similar to that in patients with elevated ALT levels. This suggests that the decision to initiate anti-HCV treatment should not be based simply on serum ALT levels, especially in patients with serum ALT concentrations >20 IU/L. Likewise, patients with serum ALT of 20–40 IU/L should not be excluded from antiviral therapy simply because of normal ALT levels. Moreover, liver biopsy may be required for decision-making regarding antiviral treatment when serum ALT levels are 20–40 IU/L in older (>50 years) and obese patients who are

reluctant to receive treatment. It has been reported that host factors such as age and obesity are associated with the development of hepatic fibrosis,5 37 and in this respect the outcomes Brefeldin_A of our study are similar to those of previous studies.5 37 Although non-invasive tests such as elastography, non-alcoholic fatty liver disease fibrosis score, and APRI or the FIB-4 score have been developed to estimate hepatic fibrosis, their accuracy has not been sufficiently validated.22 23 38 39 Moreover, these tests involve high cost and additional calculations. However, we have identified inexpensive and simple clinical parameters that are not expensive to measure and that can aid decision-making about severe hepatic fibrosis. Despite the extensive analyses using large scale pathology-based data sets, a major limitation of the current study is that the data are from a single institution and a single ethnic type.